ArticleAnimal models and experimental medicine2026
Evaluation of cardiac histology and cell death markers during the progression of diabetes in a streptozotocin-induced diabetes rat model.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The simultaneous characterization of histological alterations and distinct cell death pathways associated with diabetic cardiomyopathy (DCM) has not been comprehensively explored and may differ depending on the experimental model. We evaluated cardiac histological changes and markers of apoptosis, cell death associated with mitochondrial permeability transition pore (mPTP) opening (necrosis), and autophagy in early and advanced stages of streptozotocin (STZ)-induced diabetes in rats receiving insulin daily to prevent mortality while maintaining hyperglycemia. Adult male Sprague-Dawley rats (n = 4-5) were randomly assigned to receive STZ (diabetic group) or saline (mock) and followed up for 4 or 12 weeks. Hearts were processed for histological examination and immunohistochemical detection of active caspase-3, beclin-1, and cyclophilin D. STZ significantly increased glycemia at both time points, whereas body weight reduction was observed only at 12 weeks. No evidence of cardiac hypertrophy, fibrosis, or structural injury was detected in diabetic rats at either stage. Expression of caspase-3, beclin-1, and cyclophilin D decreased at 12 weeks compared with 4 weeks, regardless of treatment; however, cyclophilin D was elevated in diabetic hearts at 4 weeks. These results suggest an early susceptibility to mPTP opening under persistent hyperglycemia, despite the absence of overt histological damage. They also underscore the critical importance of insulin dosing and study duration when interpreting data from STZ-based models. Further studies are warranted to determine how even minimal insulin administration may shape the temporal dynamics of cell death during the progression of DCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.